Poll: Do You Agree with the FDA's Decision to Pull Avastin?

Article

This week the FDA pulled its accelerated approval of Avastin for women with HER2-negative metastatic breast cancer who have not undergone chemotherapy.

Everyone wants the best treatment available when it comes to cancer, breast cancer is no different. This week the FDA pulled its accelerated approval of Avastin for women with HER2-negative metastatic breast cancer who have not undergone chemotherapy. Avastin is still available for other types of cancer but because it is no longer approved for breast cancer insurance companies will not cover the approximately $8000.00 per month it costs. This puts breast cancer treatment out of reach for many women who say this was working for them.

Recent Videos
Self-collection and extended genotyping advance cervical cancer screening | Image Credit: linkedin.com.
New trends in cervical cancer screening: Self-collection and barriers to adherence | Image Credit: linkedin.com.
Kameelah Phillips, MD, FACOG, NCMP, is featured in this series.
Kameelah Phillips, MD, FACOG, NCMP, is featured in this series.
HPV self-collection: Benefits, limitations, and future implications | Image Credit: forhers.com
Improving pediatric HPV vaccination rates: Early initiation and addressing disparities | Image Credit: blog.nemours.org.
New cervical cancer screening guidelines: What practitioners needs to know | Image Credit: forhers.com
COVID-19 Therapy Roundtable: Focusing on inpatient care
Related Content
Study reports accelerated multiple sclerosis progression at menopause | Image Credit: © saelim - © saelim - stock.adobe.com.

Study reports accelerated multiple sclerosis progression at menopause

Celeste Krewson, Assistant Editor
January 14th 2025
Article

A recent study highlights worsened walking and motor skills in postmenopausal women with multiple sclerosis, shedding light on the need to determine hormone therapy benefits.

Read More

Pap Talk S4E15: MIRA surgical system for hysterectomy with Jean Dubuisson, MD, PhD

Pap Talk S4E15: MIRA surgical system for hysterectomy with Jean Dubuisson, MD, PhD

Celeste Krewson, Assistant Editor
December 31st 2024
Podcast

In this episode of Pap Talk, Jean Dubuisson, MD, PhD, discusses the first successful hysterectomy performed using the MIRA surgical system.

Listen

Diagnostic algorithm improves detection of uterine malignancies | Image Credit: © cameravit - © cameravit - stock.adobe.com.

Diagnostic algorithm improves detection of uterine malignancies

Celeste Krewson, Assistant Editor
January 13th 2025
Article

A novel ultrasound-based diagnostic algorithm with 98.1% sensitivity enables accurate stratification of patients with mesenchymal uterine malignancies, paving the way for personalized care.

Read More

Site Logo

How Individually Identifying More HPV Types Enables Better Patient Management and More Precise Care

September 29th 2023
Podcast

Listen

Contemporary OB/GYN week in review: FDA clears immunoassay, new elinzanetant data, and more | Image Credit: © Aleksey 159 - © Aleksey 159 - stock.adobe.com.

Contemporary OB/GYN week in review: FDA clears immunoassay, new elinzanetant data, and more

Celeste Krewson, Assistant Editor
January 10th 2025
Article

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Read More

FDA grants 510(k) clearance to chemiluminescence-based immunoassay | Image Credit: © syahrir - © syahrir - stock.adobe.com.

FDA grants 510(k) clearance to chemiluminescence-based immunoassay

Celeste Krewson, Assistant Editor
Published: January 10th 2025 | Updated: January 10th 2025
Article

The automated chemiluminescence-based immunoassay has received clearance for free testosterone, providing enhanced diagnostic options to a multitude of conditions.

Read More

© 2025 MJH Life Sciences

All rights reserved.